LYEL — Lyell Immunopharma Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapMomentum Trap

Annual balance sheet for Lyell Immunopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	615	640	546	371	247
Prepaid Expenses
Total Current Assets	626	651	555	380	261
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	167	166	142	72.9	53.6
Long Term Investments
Other Long Term Assets
Total Assets	1,127	938	750	491	340
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	46.7	37	34.5	53.8	49.4
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	198	104	95.1	108	91.8
Redeemable Preferred Stock
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	930	833	655	383	248
Total Liabilities & Shareholders' Equity	1,127	938	750	491	340
Total Common Shares Outstanding